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Purpose: Currently available hemostatic pads are effective in treating oozing bleeds, but otherwise
ineffective in more severe bleeding. This study investigates the hemostatic efﬁcacy of a new hemostatic
pad with advanced sealing properties using protein-reactive polyethylene glycol-coated collagen (PCC,
Hemopatch) versus an oxidized regenerated cellulose (ORC, Tabotamp/Surgicel Original) in a leporine
arterial bleeding model of vascular reconstruction and a porcine hepatic model of general surgery.
Methods: In both models, paired lesions were created and treated according to a randomized scheme
and evaluated up to 10 min after application (40 lesions/group/model). Arterial needle holes were
created in the femoral arteries of anesthetized rabbits and hepatic lesions were created into hepatic
parenchyma of anesthetized pigs. Both models were heparinized to mimic clinical comorbidity. Results:
In the leporine vascular surgical model, PCC provided superior hemostatic success compared to ORC at
2 min (Odds Ratio of Success: 85, 95% CI: 25.8e282) and similar hemostatic success at 10 min. In the
porcine hepatic model, PCC provided superior hemostatic success compared to ORC at 2 (98 vs 55%,
P < 0.001), 3 (93 vs 65%, P < 0.001), 4 (98 vs 68%, P < 0.001) and 5 min (95 vs 80%, P < 0.001), but similar
hemostatic success at 8 and 10 min. Discussion: PCC provided 75.4% greater hemostatic success at 2 min
in the arterial model and was at least 100 times more likely to be hemostat effective at 2 min in the
hepatic model than ORC. Conclusions: PCC provided faster hemostasis than ORC in a vascular and he-
patic surgical model with impaired coagulation.
© 2014 Baxter International, Inc. Published by Elsevier Ltd. This is an open access article under the CC BY-
NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).1. Introduction
Topical hemostats and sealants have become important tools in
the armamentarium of modern surgery due to their proven ability
to signiﬁcantly reduce bleeding complications. Key drivers for new
product developments emanate from the growing demand for ever
more minimally invasive procedures, the desire to reduce the
number of transfusions and hence reduce morbidity [1e4], and tois).
by Elsevier Ltd. This is an open accoptimize cost effectiveness in all surgical specialties [5]. While
control of bleeding is paramount to the success of all surgeries, it is
critically important in cardiovascular surgery and parenchymal
organ repair, resection and transplant.
As surgical interventions like valve repair, septal repair and
coronary artery bypass becomemore prevalent, increased diligence
is needed in securing aortic, atrial or ventricular incisions to reduce
the risk of bleeding. Moreover, re-operative surgeries increase the
complexity encountered during cardiac procedures. Patients who
require cardiac re-operations typically require higher transfusion
rates, in part because of the time-consuming dissection of scar
tissue and adhesions. Dissecting these friable tissues can be tediousess article under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-
Table 1
Bleeding score description.
Bleeding score Description
0 No bleeding.
1 Blood saturates hemostatic agent.
2 Blood visibly pools in or around hemostatic agent.
3 Blood drips from the lesion or through the hemostatic
agent, or a hematoma forms beneath the hemostatic agent.
4 Blood steadily and continuously ﬂows from the lesion or
through the hemostatic agent.
5 Blood rapidly and aggressively streams from the lesion or
through the hemostatic agent.
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Similarly, central and peripheral vascular surgery involve suture
line and anastomotic bleedings [7e9]. The challenge of achieving
adequate hemostasis is exacerbated in these procedures when the
coagulation system is compromised. This is frequently the case in
cardiac surgery when patients are treated with systemic heparin-
ization intra-operatively to prevent thrombosis, or treated peri-
operatively with platelet inhibitors [10]. Iatrogenic or clinical
coagulopathies are also seen in patients on dialysis or have acute or
chronic hepatic disease [11,12].
Partial liver resections for primary or secondary hepatic malig-
nancies are considered standard surgical interventions, yet are still
challenging because of the risk of massive intraoperative bleeding,
and the complicated biliary and vascular anatomy [13]. Improved
operating techniques and advances in instrumentation have
reduced the mortality rate associated with partial hepatic re-
sections about fourfold to today's 5% or less in most specialty
centers [14e16]. Novel devices which allow for sealing of small
vessels during the intervention include the ultrasonic dissector, the
water jet, and the focal radiofrequency ablation device [17]. Despite
these innovations, oozing of blood from the resected liver surface
may still occur. Aside from ﬁrst-time elective surgery, adhesioloysis
or repair of the liver can lead to diffuse oozing bleeds as well.
Several topical agents have been developed as adjunct therapy to
improve surgical hemostasis [5,18,19]. These topical hemostatic
agents are either (i) ﬂowable or (ii) non-ﬂowable. The ﬁrst group
comprises ﬁbrin and synthetic sealants [7,9,20], combinations of
gelatin and thrombin [21], and stand alone thrombin [22]. Synthetic
sealants, like polyethylene glycol (PEG), can effectively induce he-
mostasis by forming amechanical seal underwhich blood is trapped
and forms a solid clot [6]. The second group comprises collagenpads
[23], gelatin sponges [24], ﬁbrinogen-coated collagen [25,26] and
oxidized cellulose [27]. While ﬂowable hemostats have their utility
in deepwounds, hemostatic pads andﬂeeces arewidely used to stop
bleeding in superﬁcial surgical applications [18]. These superﬁcial
applications include suture lines and broad areas of bleeding, where
adherence and contact with the bleeding surface is required.
A hemostatic biomaterial, collagen, was coated with a protein
reactive, PEG based cross-linker; which allows for very rapid and
strong adherence of the pad to the bleeding tissue while being
pliable to ensure its utility in laparoscopic procedures. The aim of
these studies was to assess the efﬁcacy of a PEG-coated Collagen
Patch (PCC, Hemopatch) relative to oxidized regenerated cellulose
(ORC, Tabotamp) in two in vivo studies. A heparinized rabbit
femoral arterymodel was used to test the efﬁcacy of PCC in vascular
and cardiovascular surgery. A heparinized porcine hepatic square
model was used to test the efﬁcacy of PCC in general surgery.
2. Materials and methods
2.1. Hemostatic agents
Hemopatch [Sealing Hemostat] (Baxter AG, Vienna, Austria) is a
pentaerythritol polyethylene glycol ether tetra-succinimidyl glu-
tarate (NHS-PEG) monomer-coated bovine collagen pad that is
applied dry with dry or damp gauze. It is designed for open and
laparoscopic procedures. Tabotamp [Absorbable Hemostat] (Ethi-
con Inc., Somerville, NJ, USA) is hemostyptic due to a low pH, which
also denatures proteins and yields bactericidal properties [28,29].
Tabotamp is known as Surgicel Original in North America.
2.2. Surgical models
All animal activities were performed according to the Guide for
the Care and Use of Laboratory Animals and the United StatesAnimal Welfare Act or Austrian Laws Governing Animal Experi-
mentation in AAALAC accredited institutions following Institu-
tional Animal Care and Use Committee approval.2.3. Leporine vascular anastomosis model
The heparinized leporine arterial bleeding surgical model
mimics a vascular anastomosis following peripheral graft place-
ment or a vascular anastomosis following a visceral abdominal
organ transplant. Two lesions (one distal, one proximal) in each
femoral artery of twenty heparinized rabbits were created. Each
lesion was created by passing a suture needle, HR22 with approx-
imately 1 cm 2e0 polyester attached, in a distal to proximal di-
rection to create two holes in the artery. The lesions were created in
bilateral pairs by ﬁrst performing the distal pair then the proximal
pair. Bleeding rate was measured using pre-weighed gauze for 6 s
after which lesions were treated according to a randomized
scheme. The hemostatic pads were randomized in pairs such that
each animal was treated with both test items. Therefore, a total of
20 animals were used, in which a total of 2 lesions per animal were
treated with each hemostatic pad, a total of 4 lesions per animal.
Each hemostatic pad (1 cm  1 cm) was applied with digital
pressure for 2 min. All rabbits were heparinized (300 IU/kg, IV) to
achieve an activated clotting time required for peripheral vascular
surgery, 250 s [30].
Hemostatic effectiveness was assessed at 2, 3, 4, 5 and 10 min
after application, using a bleeding score from 0 to 5 (Table 1). He-
mostatic effectiveness was deﬁned as 0 and 1 [31]. Statistical sig-
niﬁcance is based on a generalized linear mixed effects model to
calculate the probability of hemostatic effectiveness consisting of
ﬁxed effects covariates. An animal-speciﬁc intercept and animal-
speciﬁc slopes for modeling the location and time effect were
included as random effects. The level of statistical signiﬁcance was
set to 5%.2.4. Porcine hepatic square model
The heparinized porcine hepatic square surgical model mimics a
hepatic capsular tear [31,32]. Two paired lesions were created in
the hepatic parenchyma by incising 1 cm  1 cm squares into the
hepatic capsule then avulsing the capsules 3e4 mm deep from the
parenchyma. Bleeding ratewas measured using pre-weighed gauze
for 6 s after which lesions were treated according to a randomized
scheme. PCC (3 cm  3 cm) and ORC (2.5 cm  3 cm) were applied
with digital pressure using gauze for 2 min. A total of 14 lesions
were created in four animals and 12 lesions were created in two
animals for a total of 80 lesions, inwhich half of the 80 were treated
with PCC and the other half with ORC. All pigs were heparinized to
maintain an activated clotting time 1.5 to 2.0 baseline to mimic
the coagulopathies associated with liver disease [11,12].
A sample size of 40 lesions per treatment groupwas determined
to be sufﬁcient to detect a difference in rates of 75 percent versus 35
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and power¼ 90% based on a standard 2 2 2 test per time point.
Logistic regressionwas used to evaluate the treatment effect at 2, 3,
4, 5, 8 and 10 min after application in two ways: assuming a pro-
portional odds model on observed bleeding score from 0 to 5 and
assuming a binomial model on success percent, where hemostatic
effectiveness was deﬁned as 0 or 1 [31]. Descriptive statistics of
model characterization were performed.
3. Results
3.1. Leporine vascular anastomosis model
The median rates of bleeding was consistent between groups
(PCC: 17.1 ± 8.6 mL/min, ORC: 15.7 ± 7.9 mL/min, N¼ 40 per group).
All lesions were an arterial spurting bleed. Based on the generalized
linear mixed effects model, the calculated probability for hemo-
static effectiveness 2 min after application is 80.1% for PCC and 4.7%
for ORC, which increases to 100% and 99.6% at 10 min, respectively
(Fig. 1). The linear mixed effects model is based on the median
bleed rate of 14.5 mL/min. The odds of hemostatic success of PCC
over the odds of hemostatic success of ORC at 2 min after appli-
cation is 85.3 (95% CI: 25.8e282).
3.2. Porcine hepatic square model
The mean direct blood pressure at the time of lesion creation
was 78 ± 13 mm Hg (Mean ± SD, N ¼ 80) with a systolic of
102 ± 13 mm Hg and diastolic of 63 ± 13 mm Hg. The median rates
of bleeding was consistent between groups (PCC: 2.5 mL/min, ORC:
2.4 mL/min, N ¼ 40 per group) with an overall range of
0.8e32.1 mL/min. The ACT of all animals were between 1.4 and
3.6 baseline throughout the study. The mean baseline PT of all
animals was 19.0 s (N¼ 6, SD¼ 1.3, Range: 17.4e21.1) and themean
terminal PT of all animals was 131.2 s (N ¼ 6, SD ¼ 53.8, Range:
34.3e170.0). The baseline APTT was not obtained as the value was
less than the minimum detection limit of 20 s. The mean terminal
APTT of all animals was 47.8 s (N ¼ 6, SD ¼ 16.3, Range: 29.0e69.7).
PCC provided superior hemostatic success relative to ORC
(Fig. 2). The hemostatic success of PCC at all time points after
application ranged between 92.5% and 97.5% (N ¼ 40). TheFig. 1. NHS-PEG Coated Collagen (PPC, Hemopatch) provided a greater probability of
hemostatic effectiveness than an oxidized regenerated cellulose (ORC, Tabotamp/Sur-
gicel Original) using a generalized linear mixed effects model based on the median
bleed rate of 14.5 mL/min in a leporine vascular anastomosis surgical model (L ¼ Left,
R ¼ Right, P¼Proximal, D ¼ Distal).hemostatic success of ORC steadily improved over time from 55% at
2 min to 97.5% at 10 min. Based on the statistical comparison using
odds ratio of hemostatic success calculated by the binomial model,
PCCwas superior to ORC at 2 (P< 0.001), 3 (P¼ 0.003), 4 (P¼ 0.004)
and 5 min (P ¼ 0.04) after application (Table 2). PCC and ORC were
not signiﬁcantly different at 8 (P¼ 0.35) and 10 (P¼ 0.87) min after
application. Consistent with hemostatic success, PCC had a lower
bleeding score at all time points (Fig. 3). Based on the statistical
comparisons using success logit ratio of bleeding score estimated
by the multinomial model, PCC was superior to ORC 2 (P < 0.001), 3
(P < 0.001), 4 (P < 0.001), 5 (P < 0.001), and 10 (P ¼ 0.04) min after
application (Table 2). PCC and ORC were not signiﬁcantly different
at 8 min after application (P ¼ 0.15) in this analysis.4. Discussion
The challenge of surgical hemostasis is greatest in the ﬁelds of
cardiovascular and parenchymal tissue repair, wherein the patient's
coagulation is either iatrogenically or clinically compromised. This
study used two animal models to investigate the efﬁcacy of a new
sealinghemostat in clinically relevantmodels to these surgicalﬁelds.
The leporine vascular surgery model mimicked a vascular anasto-
mosis performed following a vascular reconstruction. The porcine
hepatic square surgery model mimicked a capsular tear. These
models demonstrated that PCC provides greater and faster hemo-
stasis than the standard of care, ORC, in the representative animal
models. These data suggest that the sealing hemostat, PCC,may offer
greater advantage in these clinical scenarios. The difference in efﬁ-
cacy is likely due to PCC's unique dual mechanism of action.
PCC is an advanced, ready-to-use hemostatic pad designed for
open and endoscopic surgery. It consists of a thin, pliable collagen
ﬂeece coatedwith an electrophilic crosslinking agent. Upon contact
with blood and ﬂuids the crosslinking agent forms covalent bonds
with blood proteins and the underlying tissue, thus ﬁxing the pad
to the site of application and sealing of the wound. Rapid uptake of
liquid and subsequent platelet activation takes place in the pad,
where platelets get entrapped in the collagen ﬁbers resulting in the
formation of a ﬁbrin clot which leads to reliable hemostasis and
sealing of tissues. In contrast, ORC induces hemostasis via a primary
local hemostyptic action and secondary platelet activation to
induce hemostasis [18]. The hemostyptic action generated by the
low pH is created by the carboxylic acid functional groups [28,29].Fig. 2. NHS-PEG Coated Collagen (PPC, Hemopatch) provided signiﬁcantly greater
hemostatic success than an oxidized regenerated cellulose (ORC, Tabotamp/Surgicel
Original) in a porcine hepatic square model of general surgery, where statistical sig-
niﬁcance is based on an odds ratio of hemostatic success estimated by a binomial
model (*, P < 0.001; **, P ¼ 0.003; ***, P ¼ 0.004; ****, P ¼ 0.04).
Table 2
Results of the multiple logistic regression for hemostatic success based on the odds
ratio of binomial model, and for bleeding score based on the odds ratio of propor-
tional model. A 95% lower conﬁdence limit greater than 1.0 indicates statistical
signiﬁcance and favors the numerator of the comparison. The greater the value
above 1.0, the greater the signiﬁcance.
Model Time
(min)
Odds ratio
(hemopatch/
tabotamp)
Standard
error
P-value 95% C.I.
Lower Upper
Binomial model
of hemostatic
success
2 149 1.49 0.0008 8.12 2751
3 17.2 0.94 0.0026 2.70 109
4 39.6 1.26 0.0036 3.33 472
5 8.21 1.03 0.0415 1.08 62.2
8 2.84 1.13 0.3549 0.31 25.9
10 0.79 1.45 0.8680 0.05 13.4
Proportional
model of
bleeding
score
2 99.7 0.80 <0.0001 20.9 475
3 49.3 0.73 <0.0001 11.8 205
4 19.4 0.60 <0.0001 5.94 63.3
5 13.9 0.64 <0.0001 3.99 48.7
8 2.52 0.64 0.1508 0.71 8.92
10 5.13 0.80 0.0418 1.06 24.8
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difference observed in the heparinized models. While ORC was
dependent on thrombin to reinforce the primary platelet plug
initiated by its hemostyptic action, PCC immediately seals the
bleeding then secondarily induces the platelet plugwhich leads to a
ﬁbrin clot. The ability for PCC to seal the bleeding, does not subject
the platelet plug to be vulnerable to failure as with ORC. Based on
these differences, PCC is then also likely to provide similar hemo-
static efﬁcacy in patients treated with anti-Factor Xa, clopidogrel
(Plavix) or acetylsalicylic acid (ASA, Aspirin).
As demonstrated in these animal models, the NHS-PEG chem-
istry works independent of the patient's coagulation status. While
designed to provide a tight seal, the collagen component triggers
coagulation via contact activation and promotion of platelet ag-
gregation [33]. In regard to heparin and anti-Factor Xa, collagen's
main affect is to induce primary hemostasis via induction of
platelet activation. This is independent of secondary hemostasis
which is the target of heparin and anti-Xa therapy. In regard to
clopidogrel and ASA, both agents act on plateletsda target for
collagen. Clopidogrel's active metabolite, activated through cyto-
chrome P450-2C19, inhibits ADP binding to the thrombocyteFig. 3. NHS-PEG Coated Collagen (PPC, Hemopatch) signiﬁcantly reduced bleeding
greater than an oxidized regenerated cellulose (ORC, Tabotamp/Surgicel Original) in a
porcine hepatic square model of general surgery, where statistical signiﬁcance is based
on an odds ratio of hemostatic success estimated by a multinomial model (*, P < 0.001;
**, P ¼ 0.04).receptor P2Y12, effectively blocking thrombocyte activation
through the glycoprotein GPIIb/IIIa-receptor complex [34]. ASA
inhibits thrombocyte aggregation through a different mechanism,
namely by inhibiting cyclooxygenases COX-1 and COX-2. Collagen,
however, signals through the a2b1 integrin GPIa-IIa receptor, the
GPVI receptor and the GPIb-IX-V/vWF pathways. Hence collagen's
effect on platelet activation should be independent of the pathways
targeted by clopidogrel and ASA.
While these theoretical considerations support the principle of
PCC being effective in patients on anti-platelet therapy, it is very
difﬁcult to make quantitative predictions. As to the effectiveness of
PCC under heparinized conditions, the results obtained in the two
heparinized animal models suggest its effectiveness in human pa-
tients who receive heparin. The clinical efﬁcacy, however, must be
validated in humans as an advanced hemostatic pad within the
non-ﬂowable hemostatic armamentarium.
In addition to PCC, three other self-adherent, non-ﬂowable he-
mostatic agents have been described in literature [35e37]. Each of
the agents has either a collagen or ORC backing, which is then
modiﬁed to be self-adherent. Collagen is a well-studied biomaterial
that has innate hemostatic capabilities. ORC is also well-studied
and has an innate hemostyptic and bactericidal properties due to
its very acidic pH (pH ¼ 2.5) [28,29]. Though the low pH of ORC
degrades coagulation proteins [27], it is used as a backing for non-
ﬂowable hemostats [35,36].
The synthetic self-adherent mechanisms reported are a poly-
ethylene glycol monomer or a combination of human-derived
ﬁbrinogen and thrombin. The use of synthetic materials obviates
the likelihood of human viral transmission and has a faster time to
adherence relative to ﬁbrinogen and thrombin materials [35]. Since
all four agents are not commercially available at this time, a
comprehensive comparison is needed to determine the advantages
and disadvantages of the agents.
5. Conclusions
A new sealing hemostat (PCC, Hemopatch) provides greater and
faster hemostasis than oxidized cellulose (ORC, Tabotamp) in a
heparinized leporine vascular anastomosis model and a heparin-
ized porcine hepatic square model. Based on the ﬁndings of this
study, the mode of action of PCC is also speculated to be effective in
patients with clinical coagulopathy comorbidities.
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